{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:53:52Z","timestamp":1777870432643,"version":"3.51.4"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82200786"],"award-info":[{"award-number":["82200786"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82070705"],"award-info":[{"award-number":["82070705"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81770670"],"award-info":[{"award-number":["81770670"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81873595"],"award-info":[{"award-number":["81873595"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Oriental Talent Plan Outstanding Program 2023, Shanghai Municipal Key Clinical Specialty","award":["shslczdzk02503"],"award-info":[{"award-number":["shslczdzk02503"]}]},{"name":"Shanghai Science and Technology Talent Program","award":["19YF1450300"],"award-info":[{"award-number":["19YF1450300"]}]},{"name":"Research Projects of Shanghai Science and Technology Committee","award":["17411972100"],"award-info":[{"award-number":["17411972100"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"DOI":"10.1007\/s40620-025-02341-2","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T15:51:50Z","timestamp":1753717910000},"page":"1797-1808","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of TRF-budesonide in IgA nephropathy treatment: a meta-analysis"],"prefix":"10.1093","volume":"38","author":[{"given":"Jiayi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongqin","family":"Tai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenchen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiguo","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"issue":"3","key":"2341_CR1","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/j.ajkd.2021.01.024","volume":"78","author":"P Pattrapornpisut","year":"2021","unstructured":"Pattrapornpisut P, Avila-Casado C, Reich HN (2021) IgA nephropathy: core curriculum 2021. Am J Kidney Dis 78(3):429\u2013441. https:\/\/doi.org\/10.1053\/j.ajkd.2021.01.024. (Epub 2021 Jul 9. PMID: 34247883)","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2341_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41572-023-00476-9","volume":"9","author":"E Stamellou","year":"2023","unstructured":"Stamellou E, Seikrit C, Tang SCW, Boor P, Tesa\u0159 V, Floege J, Barratt J, Kramann R (2023) IgA nephropathy. Nat Rev Dis Primers 9(1):67. https:\/\/doi.org\/10.1038\/s41572-023-00476-9. (PMID: 38036542)","journal-title":"Nat Rev Dis Primers"},{"key":"2341_CR3","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1681\/ASN.2010040355","volume":"22","author":"F Berthoux","year":"2011","unstructured":"Berthoux F et al (2011) Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol 22:752\u2013761","journal-title":"J Am Soc Nephrol"},{"key":"2341_CR4","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1681\/ASN.2018101017","volume":"30","author":"S Jarrick","year":"2019","unstructured":"Jarrick S et al (2019) Mortality in IgA nephropathy: a nationwide population-based cohort study. J Am Soc Nephrol 30:866\u2013876","journal-title":"J Am Soc Nephrol"},{"key":"2341_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091756","volume":"9","author":"T Moriyama","year":"2014","unstructured":"Moriyama T et al (2014) Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan. PLoS ONE 9:e91756","journal-title":"PLoS ONE"},{"issue":"10","key":"2341_CR6","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1681\/ASN.2011050464","volume":"22","author":"H Suzuki","year":"2011","unstructured":"Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, Wyatt RJ, Scolari F, Mestecky J, Gharavi AG, Julian BA (2011) The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22(10):1795\u20131803. https:\/\/doi.org\/10.1681\/ASN.2011050464. (Epub 2011 Sep 23. PMID: 21949093; PMCID: PMC3892742)","journal-title":"J Am Soc Nephrol"},{"key":"2341_CR7","first-page":"629","volume":"118","author":"H Suzuki","year":"2008","unstructured":"Suzuki H et al (2008) IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Investig 118:629\u2013639","journal-title":"J Clin Investig"},{"key":"2341_CR8","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1681\/ASN.2011050464","volume":"22","author":"H Suzuki","year":"2011","unstructured":"Suzuki H et al (2011) The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22:1795\u20131803","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"2341_CR9","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00281-021-00888-3","volume":"43","author":"J Floege","year":"2021","unstructured":"Floege J, Rauen T, Tang SCW (2021) Current treatment of IgA nephropathy. Semin Immunopathol 43(5):717\u2013728. https:\/\/doi.org\/10.1007\/s00281-021-00888-3. (Epub 2021 Sep 8. PMID: 34495361; PMCID: PMC8551131)","journal-title":"Semin Immunopathol"},{"issue":"2","key":"2341_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ekir.2023.11.026","volume":"9","author":"H Selvaskandan","year":"2023","unstructured":"Selvaskandan H, Barratt J, Cheung CK (2023) Novel treatment paradigms: primary IgA nephropathy. Kidney Int Rep 9(2):203\u2013213. https:\/\/doi.org\/10.1016\/j.ekir.2023.11.026. (PMID:38344739; PMCID:PMC10851020)","journal-title":"Kidney Int Rep"},{"key":"2341_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.926517","volume":"13","author":"J Liao","year":"2023","unstructured":"Liao J, Zhou Y, Zhao S, Huang K, Chen P, Wu Y et al (2023) Current knowledge of targeted-release budesonide in immunoglobulin a nephropathy: a comprehensive review. Front Immunol 13:926517. https:\/\/doi.org\/10.3389\/fimmu.2022.926517","journal-title":"Front Immunol"},{"issue":"3","key":"2341_CR12","doi-asserted-by":"publisher","first-page":"1175088","DOI":"10.3389\/fneph.2023.1175088","volume":"23","author":"SM Noor","year":"2023","unstructured":"Noor SM, Abuazzam F, Mathew R, Zhang Z, Abdipour A, Norouzi S (2023) IgA nephropathy: a review of existing and emerging therapies. Front Nephrol 23(3):1175088. https:\/\/doi.org\/10.3389\/fneph.2023.1175088. (PMID:37675358; PMCID:PMC10479631)","journal-title":"Front Nephrol"},{"issue":"10084","key":"2341_CR13","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","volume":"389","author":"BC Fellstr\u00f6m","year":"2017","unstructured":"Fellstr\u00f6m BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, Floege J, Hetzel G, Jardine AG, Locatelli F, Maes BD, Mercer A, Ortiz F, Praga M, S\u00f8rensen SS, Tesar V, Del Vecchio L, NEFIGAN Trial Investigators (2017) Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet 389(10084):2117\u20132127. https:\/\/doi.org\/10.1016\/S0140-6736(17)30550-0. (Epub 2017 Mar 28. PMID: 28363480)","journal-title":"Lancet"},{"issue":"2","key":"2341_CR14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","volume":"103","author":"J Barratt","year":"2023","unstructured":"Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH, NefIgArd Trial Investigators (2023) Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int 103(2):391\u2013402. https:\/\/doi.org\/10.1016\/j.kint.2022.09.017. (Epub 2022 Oct 19. PMID: 36270561)","journal-title":"Kidney Int"},{"key":"2341_CR15","doi-asserted-by":"publisher","unstructured":"Lafayette R, Kristensen J, Stone A, Floege J, Tesa\u0159 V, Trimarchi H, Zhang H, Eren N, Paliege A, Reich HN, Rovin BH, Barratt J, NefIgArd Trial Investigators (2023) Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet 402(10405):859\u2013870. https:\/\/doi.org\/10.1016\/S0140-6736(23)01554-4. (Epub 2023 Aug 14. PMID: 37591292). Erratum in: Lancet. 2023 Sep 9;402(10405):850. https:\/\/doi.org\/10.1016\/S0140-6736(23)01851-2","DOI":"10.1016\/S0140-6736(23)01554-4"},{"issue":"12","key":"2341_CR16","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.34067\/KID.0000000583","volume":"5","author":"H Zhang","year":"2024","unstructured":"Zhang H, Lafayette R, Wang B, Ying L, Zhu Z, Stone A, Kristensen J, Barratt J (2024) Efficacy and safety of nefecon in patients with immunoglobulin A nephropathy from mainland China: 2-year NefIgArd trial results. Kidney360 5(12):1881\u20131892. https:\/\/doi.org\/10.34067\/KID.0000000583","journal-title":"Kidney360"},{"issue":"1","key":"2341_CR17","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1159\/000540283","volume":"49","author":"D Shang","year":"2024","unstructured":"Shang D, Guan Y, Liu S, Hao C, Lai L (2024) Effectiveness and safety of spironolactone in the treatment of IgA nephropathy: a retrospective self-controlled study. Kidney Blood Press Res 49(1):687\u2013698. https:\/\/doi.org\/10.1159\/000540283. (Epub 2024 Jul 23. PMID: 39043158)","journal-title":"Kidney Blood Press Res"},{"issue":"23","key":"2341_CR18","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","volume":"373","author":"T Rauen","year":"2015","unstructured":"Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, Panzer U, Peters H, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JF, Hilgers RD, Floege J, STOP-IgAN Investigators (2015) Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 373(23):2225\u20132236. https:\/\/doi.org\/10.1056\/NEJMoa1415463. (PMID: 26630142)","journal-title":"N Engl J Med"},{"issue":"4","key":"2341_CR19","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","volume":"98","author":"T Rauen","year":"2020","unstructured":"Rauen T, Wied S, Fitzner C, Eitner F, Sommerer C, Zeier M, Otte B, Panzer U, Budde K, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JFE, Hilgers RD, Floege J, STOP-IgAN Investigators (2020) After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int 98(4):1044\u20131052. https:\/\/doi.org\/10.1016\/j.kint.2020.04.046. (Epub 2020 May 22. PMID: 32450154)","journal-title":"Kidney Int"},{"issue":"19","key":"2341_CR20","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2022.5368","volume":"327","author":"J Lv","year":"2022","unstructured":"Lv J, Wong MG, Hladunewich MA, Jha V, Hooi LS, Monaghan H, Zhao M, Barbour S, Jardine MJ, Reich HN, Cattran D, Glassock R, Levin A, Wheeler DC, Woodward M, Billot L, Stepien S, Rogers K, Chan TM, Liu ZH, Johnson DW, Cass A, Feehally J, Floege J, Remuzzi G, Wu Y, Agarwal R, Zhang H, Perkovic V, TESTING Study Group (2022) Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 327(19):1888\u20131898. https:\/\/doi.org\/10.1001\/jama.2022.5368. (PMID: 35579642; PMCID: PMC9115617)","journal-title":"JAMA"},{"issue":"1","key":"2341_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12882-022-02661-6","volume":"23","author":"M Liang","year":"2022","unstructured":"Liang M, Xiong L, Li A, Zhou J, Huang Y, Huang M, Zhang X, Shi H, Su N, Wei Y, Jiang Z (2022) The effectiveness and safety of corticosteroid therapy for IgA nephropathy with crescents: a prospective, randomized, controlled study. BMC Nephrol 23(1):40. https:\/\/doi.org\/10.1186\/s12882-022-02661-6. (PMID:35062886; PMCID:PMC8780312)","journal-title":"BMC Nephrol"},{"key":"2341_CR22","doi-asserted-by":"publisher","unstructured":"Heo YA (2021) Budesonide\/glycopyrronium\/formoterol: a review in COPD. Drugs 81(12):1411\u20131422. https:\/\/doi.org\/10.1007\/s40265-021-01562-6. (Epub 2021 Aug 3. PMID: 34342835; PMCID: PMC8384783). Erratum in: Drugs. 2021 Sep;81(14):1699. https:\/\/doi.org\/10.1007\/s40265-021-01595-x","DOI":"10.1007\/s40265-021-01562-6"},{"key":"2341_CR23","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1093\/ndt\/gfr052","volume":"26","author":"HK Smerud","year":"2011","unstructured":"Smerud HK, Barany P, Lindstrom K, Fernstrom A, Sandell A, Pahlsson P et al (2011) New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria. Nephrol Dial Transplant 26:3237\u20133242. https:\/\/doi.org\/10.1093\/ndt\/gfr052","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2341_CR24","doi-asserted-by":"publisher","first-page":"20119","DOI":"10.1038\/s41598-023-47393-1","volume":"13","author":"B Obri\u0219c\u0103","year":"2023","unstructured":"Obri\u0219c\u0103 B, Vornicu A, Mocanu V, Dimofte G, Andronesi A, Bobeic\u0103 R, Jurubi\u021b\u0103 R, Sorohan B, Caceaune N, Ismail G (2023) An open-label study evaluating the safety and efficacy of budesonide in patients with IgA nephropathy at high risk of progression. Sci Rep 13(1):20119. https:\/\/doi.org\/10.1038\/s41598-023-47393-1. (PMID:37978255; PMCID:PMC10656480)","journal-title":"Sci Rep"},{"issue":"6","key":"2341_CR25","doi-asserted-by":"publisher","first-page":"755","DOI":"10.4103\/1319-2442.390255","volume":"33","author":"U Lingaraj","year":"2022","unstructured":"Lingaraj U, Mallapur S, Viswanathan A, Vankalakunti M (2022) Clinical response to intestine-targeted steroid therapy in biopsy-proven immunoglobulin A nephropathy. Saudi J Kidney Dis Transpl 33(6):755\u2013760. https:\/\/doi.org\/10.4103\/1319-2442.390255. (Epub 2023 Nov 29. PMID: 38018717)","journal-title":"Saudi J Kidney Dis Transpl"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-025-02341-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-025-02341-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-025-02341-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:59:17Z","timestamp":1777564757000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/38\/7\/1797\/8457450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":25,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["2341"],"URL":"https:\/\/doi.org\/10.1007\/s40620-025-02341-2","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"4 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable for a meta-analysis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Not applicable for a meta-analysis.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}